Vaxcyte Corporate Presentation

4 Key Corporate Highlights Next-Generation Vaccine Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise о Large Market Opportunity for PCV Franchise Protein Synthesis Cell-Free Platform Disciplined Target Selection • • Scalable PCV platform enabling broader-spectrum PCVS: VAX-24 & VAX-XP - Lead candidate: VAX-24 24-valent PCV with potential to replace SOC Anticipated IND filing in Q1:22(1) Anticipated Phase 1/2 data readout in late '22- early '23(1) (1) Guidance provided as of November 10, 2021. • Leverages site- specific conjugation • • Permits production of "tough-to-make" antigens Demonstrated speed, flexibility, and scalability . • Robust Development Pipeline Aligned Critical Resources Targets well-defined >$7B market segment Honors well- understood PCV MOA Leverages established surrogate immune • Platform unlocks large market opportunities: - VAX-A1: Novel Group A Strep conjugate vaccine VAX-PG: Novel periodontitis therapeutic endpoints and clinical pathways vaccine Strategic alignment with Lonza (manufacturing) Seasoned management team, directors and advisors • Cash, cash equivalents and investments of $318.3M at 9/30/21

View entire presentation